Results 271 to 280 of about 539,919 (309)

Lactate Activates the HCAR1/β‐Arrestin2/PP2A Signaling Axis to Mediate STAT1/2 Dephosphorylation and Drive Osteosarcoma Progression

Advanced Science, EarlyView.
In the present study, it is found that in osteosarcoma, lactate‐activated HCAR1 promotes β‐arrestin 2 translocation from cytoplasm to nucleus. In the nucleus, β‐arrestin 2 recruits PP2A to the activated STAT1/2 dimers, mediating STAT1/2 dephosphorylation and inhibiting the transcription of downstream anti‐oncogenes to promote OS progression.
Zhitao Han, Qi Jia, Guangjian Bai, Zhao Li, Jin Zeng, Zhenhua Wang, Jing Zhang, Jiashi Cao, Baoquan Xin, Yonggang Liu, Jingyu Shen, Lining Wang, Xing Huang, Chunlei Zhang, Kai Tong, Fenglei Dai, Yajie Zhang, Weina Zhu, Songyi Cheng, Yuanming Chen, Xinghai Yang, Guanghui Chen, Zhenhua Zhou, Yong Ma, Weibo Liu, Ting Wang, Tielong Liu   +26 more
wiley   +1 more source

Gut microbiota shapes cancer immunotherapy responses. [PDF]

NPJ Biofilms Microbiomes
Lei W, Zhou K, Lei Y, Li Q, Zhu H.
europepmc   +1 more source

Tumor‐Derived CDC37 Inhibits Antigen Cross‐Presentation in Dendritic Cells and Impairs Anti‐Tumor Immunity in Breast Cancer

Advanced Science, EarlyView.
Extracellular vesicle (EV)‐packaged CDC37 are released from TMBhiCTLlo breast cancer cells with high CDC37 expression, and internalized into endo/phagosomes of dendritic cells (DCs). Within these compartments, CDC37 locked HSP90–antigen complex, preventing antigen release into the cytosol.
Ruxin Wang, Yunyi Zhang, Xiangyu Meng, Jianli Zhao, Yue Xing, Qian Ouyang, Ning Zhang, Huiping Chen, Nanyan Miao, Erwei Song, Di Huang   +10 more
wiley   +1 more source

Emerging roles of KIR2DL4 in cancer immunotherapy. [PDF]

Breast Cancer
Li W, Zheng G, Zhang S.
europepmc   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers

Advanced Science, EarlyView.
Tumor‐informed circulating tumor DNA (ctDNA) analysis identifies patients with advanced non‐small cell lung cancer (NSCLC) who benefit from first‐line immunotherapy plus chemotherapy. Longitudinal ctDNA monitoring further reflects therapeutic response and predicts prognosis beyond imaging.
Kailun Fei, Jie Zhao, Jiachen Xu, Jianchun Duan, Chengcheng Li, Wenchuan Xie, Jia Zhong, Guoqiang Wang, Yu Xu, Boyang Sun, Rui Wan, Hua Bai, Qinxiang Guo, Wei Guo, Shangli Cai, Zhijie Wang, Jie Wang   +16 more
wiley   +1 more source

Hydrogel-Based Vaccines: A Promising Approach for Cancer Immunotherapy. [PDF]

Int J Nanomedicine
Zhang W, Zhang Q, Cai J, He J, Xu Z, Chen X, Chen G.   +6 more
europepmc   +1 more source

TREM2‐Mediated Cholesterol Efflux in Macrophages Inhibits Anti‐Tumor Immunity via Limitation of CD4+ T and NK Cells

Advanced Science, EarlyView.
Impaired anti‐tumor immunity is mediated by TREM2 + macrophages in non‐small cell lung cancer. TREM2 + macrophages prevent anti‐tumor immunity depending on the limitation of CD4 + T and NK cells. TREM2 promotes cholesterol efflux via ABCA1 to limit the production of CX3CL1 in macrophages.
Yunhan Wang, Weina Yu, Xinxin Wang, Qitai Zhao, Qingyang Lei, Aitian Li, Shasha Liu, Tian Wang, Li Yang, Yi Zhang   +9 more
wiley   +1 more source

Asia's emergence in cancer immunotherapy: challenges and opportunities. [PDF]

J Immunother Cancer
Li Y, Yeong J, Fox BA, Sun C.
europepmc   +1 more source

Pancreatic cancer as a target for adoptive T-cell immunotherapy.

, 2007
John E. Anderson
openalex   +1 more source